Personalized at-home neurofeedback compared to long-acting methylphenidate in children with ADHD: NEWROFEED, a European randomized noninferiority trial
For the treatment of attention-deficit hyperactivity disorder (ADHD), one of the promising interventions is neurofeedback. In NEWROFEED, a prospective, multicentre, randomized (3:2), reference drug-controlled trial, researchers assessed the noninferiority of personalized at-home neurofeedback (NF) training vs methylphenidate in the treatment of children with ADHD...Read the full article on Journal of Child Psychology and Psychiatry.
Other Articles in this Edition
Drug relieves persistent daydreaming, fatigue, and brain sluggishness in adults with ADHD
Managing attention deficit disorder by training the brain
Participation in after-school activities decreases ADHD severity
FDA Approves Updated Prescribing Information for Extended-Release ADHD Drug
It’s game on for Akili as it launches digital campaign for first FDA-approved ADHD video game
Ending the mental health stigma in the tech community
What to do if a child with ADHD cannot sleep
Single people with ADHD describe what it’s like to date when your brain is wired differently
Increased risk of ADHD at short and long interpregnancy intervals in a national birth cohort